NEBL and urinary bladder carcinoma: LASP2 was found to be downregulated in several human cancers, including hepatocellular carcinoma (Li et al, 2020), colorectal cancer (Wang et al, 2017), nasopharyngeal carcinoma (Yang et al, 2020), and bladder cancer (Yang et al, 2018).